Immunologic and morphologic typing as prognostic factor in M1 acute myeloblastic leukemia.
Thirty-two patients diagnosed in the Gustave Roussy Hospital between 1981 and 1988 were divided into three groups according to the morphology of the predominant blast cells in the bone marrow. Cytochemical reaction in the form of Sudan Black, myeloperoxidase reaction and immunological typing were performed for 13 patients. Twelve patients were treated with protocol AML6, eight with protocol AML8, one with protocol LAL16, and the rest with other types of protocols. To a certain extent morphological maturation was correlated with antigenic differentiation. The lack of expression of Ia antigen (HLA-DR) identified patients with a low rate of relapse during the first year of remission, and patients with My7 positive leukemia had a worse prognosis than did patients with My7 negative leukemia. The 2 patients positive for MO1 antigen did not achieve remission, and out of 9 patients who were negative for MO1 antigen only 2 achieved remission for approximately 1 year. Only 1 of 3 patients with biphenotypic leukemia achieved remission for more than 1 year.
el Zimeity
M
M
Department of Medicine, Ain Shams University, Cairo, Egypt.
Bayle
C
C
Sabbour
M S
MS
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D007124:Immunoenzyme Techniques; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D003630:Daunorubicin